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Abstract: Protease inhibitors that were identified from amphibian skin secretions with low molecular
weights and potent inhibitory activity were thought to be potential candidates for novel peptide
drugs. Here, a novel peptide with trypsin inhibitory activity was found in the skin secretion of
the Chinese bamboo leaf odorous frog, Odorrana versabilis. Based on the sequence alignments of
sequencing results, the novel peptide (ALKYPFRCKAAFC) was named as Kunitzin-OV. The synthetic
replicate of Kunitzin-OV was subjected to a series of functional assays, and it exhibited a trypsin
inhibitory activity with a Ki value of 3.042 µM, whereas, when Lys-9 at P1 position was substituted
by Phe, trypsin inhibitory activity was undetected and the chymotrypsin inhibitory activity was
optimized with a Ki value of 2.874 µM. However, its protease-binding loop was catabolized by trypsin
during the trypsin cleavage test. In conclusion, Kunizin-OV is a novel peptide with trypsin inhibitory
activity as a member of kunitzins, which is a non-typical Kunitz-like trypsin inhibitor with a highly
conserved reactive site (K-A) and quite a short sequence.
Keywords: frog skin secretion; trypsin inhibitor; Kunitz-type inhibitors; kunitzins
1. Introduction
Trypsin inhibitors (TIs), which belong to the serine peptidase inhibitors family, can competitively
bind to trypsin via a substrate-like manner to regulate the action of trypsin [1]. These inhibitors are
widespread in both plants [2] and animals [3,4], and have been described to possess great clinical
significance in cancer prevention [5], treatment of obesity [6], and celiac disease therapy [7].
Skin secretions from amphibians are an abundant source of multi-functional bioactive peptides, and
these peptides are useful agents for hydration, and regulating and strengthening defensive mechanisms [8].
Over the past decades, many different types of protease inhibitors have been identified from amphibian
secretions, and these inhibitors with low molecular weights and potent inhibitory activity were thought
to be potential candidates for novel peptide drugs [1]. According to the similarities of structural
domains, sequences, reactive sites, and mechanisms, these inhibitors can be classified as different
types (e.g., Kazal-, Bowman–Birk-, and Kunitz-type) [9]. For example, Kazal-type inhibitors have
been isolated from phyllomedusine frogs [10], Bowman–Birk inhibitors from Odorrrana frogs [11],
and Kunitz-type inhibitors from the tomato frogs [3] and ranid frogs [12]. Among these three frog
skin-derived inhibitors, Kunitz-type has been the least studied.
Furthermore, Kunitz-type inhibitors are also known as bovine pancreatic trypsin inhibitor
(BPTI)-like proteins. While BPTI is the classic member of this family of proteins and was the first
Biomolecules 2019, 9, 254; doi:10.3390/biom9070254 www.mdpi.com/journal/biomolecules
Biomolecules 2019, 9, 254 2 of 14
Kunitz-type protease inhibitor described, it has relatively broad specificity inhibiting trypsin as well as
chymotrypsin and elastase-like serine (pro) enzymes [13]. In general, Kunitz-type inhibitors consist
of 50 to 60 amino acid residues and are stabilized by a disulphide bond-rich structure, and a highly
exposed P1 active site residue for interacting with proteases (trypsin mostly) is usually arginine or
lysine [13,14].
Odorous frogs are distributed in East Asia and the surrounding areas, and their skin secretions have
been well studied with several trypsin inhibitors from these species having been reported [11,14,15].
As a member of the Odorrana genus, Odorrana versabilis (O. versabilis) is chosen as a research object,
which has a great potential to provide novel and functional protease inhibitors.
In this study, the cloning of skin-derived cDNAs and the identification and structural characterisation
of a novel peptide with potent trypsin inhibitory activity are described. According to bioinformatic
analysis, this peptide is a member of the Kunitz-type inhibitor family with a canonical Kunitz-type reactive
centre. Meanwhile, a P1-substituted analogue is also synthesized and evaluated.
2. Materials and Methods
2.1. Specimen Biodata and Secretion Acquisition
Eight specimens of O. versabilis (6–8 cm snout-to-vent length, sex undetermined) were collected in
the field in China. All frogs were kept in a vivarium at 25 ◦C under a 12 h/12 h day/night cycle and were
fed crickets three times per week. The collection of skin secretion was performed as in the previous
study [10], and the secretion was finally lyophilized and stored at −20 ◦C before analysis. This study
was approved by the Nanjing University of Chinese Medicine Ethical Review Board—Approval Code:
SYXK (SU) 2018-0048.
2.2. Molecular Cloning of Kunitzin-OV Precursor-Encoding cDNA from the Skin Secretion-Derived cDNA
Library of O. versabilis
The lyophilized skin secretion was subjected to a series of procedures including mRNA
isolation, cDNA library construction, cloning, and sequencing to obtain the biosynthetic precursor of
Kunitzin-OV [10]. Specially, for Kunitzin-OV, 3′-RACE was facilitated by a nested universal primer
(NUP) (supplied by the kit) and a sense primer (REry-3: 5′-GAWYYAYYHRAGCCYAAADATG-3′),
which was designed to a highly conserved domain of the 5′-untranslated region of previously
characterized antimicrobial peptide cDNAs from Rana species.
2.3. Identification and Structural Analysis of Kunitzin-OV from Skin Secretion of O. veserbilis
Lyophilized skin secretion was dissolved and then subjected to reverse-phase HPLC using a
Waters gradient reverse phase high-performance liquid chromatography (HPLC) system as detailed in
the previously published article [11]. The molecular masses of peptides in each fraction were further
analysed by use of a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass
spectrometer (Voyager DE, PerSeptive Biosystems, Foster City, CA, USA), and selected fractions were
then infused into an LCQ Fleet ion trap electrospray mass spectrometer (Thermo Fisher Scientific, San
Francisco, CA, USA) followed by trapping of suitable ions for MS/MS fragmentation [11].
2.4. Solid-Phase Peptide Synthesis of Kunitzin-OV and F9-Kunitzin-OV
Kunitzin-OV and F9-Kunitzin-OV were synthesized by standard Fmoc chemistry using a Tribute™
peptide synthesizer (Protein Technologies, Tucson, AZ, USA) that was described in the previous
study [16]. The crude peptides were purified and identified via the combination of HPLC and
MS technology. The lyophollized pure peptides were subjected to a series of functional assays.
The physicochemical properties of the peptides were computed using ProtParam.
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2.5. Minimal Inhibitory Concentration Assay of Kunitzin-OV and Phe-Substituted Analogue
Staphylococcus aureus (NCTC 10788), Escherichia coli (NCTC 10418), and Candida albicans (NCPF 1467)
were applied in the antimicrobial test. They all were cultured in Mueller-Hinton Broth (MHB). The broth
dilution method was applied to detect the minimal inhibitory concentrations (MICs) of peptides and
the peptide concentrations were arranged from 1 µM to 512 µM in a two-fold dilution [16]. Peptides
were incubated with subcultured bacteria cells (5 × 105 cfu/mL) and each concentration was performed
in seven replicates.
2.6. Haemolysis Assay
As described in the previous study [16], a suspension of horse red blood cells (4%, v/v) (TCS
Biosciences, Botolph Claydon, Buckingham, UK) was incubated with peptides of the concentration
range of 1 µM to 512 µM at 37 ◦C for 2 h to determine the peptide haemolytic activity. The positive
control employed 1% TritonX-100 (Sigma, UK).
2.7. E. coli Cell Membrane Permeability Assay of Kunitzin-OV
Kunitzin-OV was prepared at its (the minimum, inhibitory concentration) MIC and then incubated
with subcultured E. coli cells (1 × 108 cfu/mL), after that, a SYTOXTM green nucleic acid stain (Life
Technologies, Paisley, UK) was applied for the determination of E. coli cell viability [17]. Moreover,
the cell-penetrating peptide melittin (512 µM) was served as a positive control, while sodium
phosphate-buffered saline (PBS) was served as a negative control.
2.8. Trypsin/Chymotrypsin Inhibition Assay
The inhibitory activity of peptides towards trypsin and chymotrypsin was tested the same as
detailed in Wang’s study [11]. Peptides were initially prepared in a range of 10−3–10−6 M and then
diluted to 16 concentrations. Each dilution was tested in duplicates. Additionally, Phe-Pro-Arg-AMC
and Succinyl-Ala-Ala-Pro-Phe-NHMec (obtained from Bachem, UK) were served as substrates for
trypsin and chymotrypsin, respectively.
2.9. Trypsin Cleavage of Kunitzin-OV
One milligram of synthetic Kunitzin-OV was subjected to the trypsin cleavage assay, following the
method described in the previous study [12], with a minor difference. Briefly, the enzymatic reactions
were stopped at 0, 1, 2, 5, 10, and 20 min, and every sample was dropped on the 100-well target plate
and subjected to MALDI-TOF analysis.
3. Results
3.1. Molecular Cloning and Sequencing Analysis of Kunitzin-OV
From the skin-derived cDNA library of Odorrana versabilis, the cDNA encoding the biosynthetic
precursor of a putative novel bioactive peptide named Kunitzin-OV was consistently and repeatedly
cloned. The open-reading frame of this cloned precursor consisted of 63 amino acid residues, which
included a 22 amino acid residues signal peptide and a mature peptide of 13 amino residues. The putative
peptide sequence was preceded by two successive basic amino acids, Lysine (K) and Arginine (R),
which represented a typical cleavage site. A single disulphide bond (Cysteine 8-3) was located at the
C-terminal (Figure 1). As the Basic Local Alignment Search Tool (NCBI-BLAST) analysis and sequence
alignments showed, this novel peptide shares an identical C-terminal part with previously found
kunitzins (Figure 2). The biosynthetic precursor encoding cDNA of Kunitzin-OV was deposited into
GenBank with an accession number of MK965543.
Biomolecules 2019, 9, 254 4 of 14
Biomolecules 2019, 9, x FOR PEER REVIEW 4 of 13 
 
Figure 1. The open-reading frame of the biosynthetic precursor of Kunitzin-OV. The putative signal 
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After a 240 min gradient reverse-phase high-performance liquid chromatography (HPLC) 
analysis, each fraction was identified by matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF MS). After comparison of the computed and the determined 
molecular masses of Kunitzin-OV, the elution site of the peptide was confirmed, while the peptide 
structure was characterized by tandem mass spectrometry (MS/MS) fragmentation sequencing 
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Figure 1. The open-reading frame of the biosynthetic precursor of Kunitzin-OV. The putative signal
peptide is double-underlined, the mature peptide is single-underlined, and an asterisk indicates the
stop codon.
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Figure 2. The primary structure of the novel Kunitzin-OV from Odorrana versabilis skin secretion
compared with other kunitzins. Fully conserved residues are highlighted.
3.2. Identification and Structural Characterisation of Kunitzin-OV
After a 240 min gradient reverse-phase high-performance liquid chromatography (HPLC)
analysis, ea h fraction was id ifi d by m trix-assisted lase desorption onization time-of-flight mass
spectrom try (MALDI-TOF MS). After co pa ison of the computed and the determined m lecular
e of Kunitzin-OV, the elution site of the peptide wa confirm d, while he peptide structure was
characterized by tandem mass spec rometry (MS/MS) fragmentation equencing (Figur 3).
3.3. Synthesis of Kunitzin-OV and Phe-Substituted Variant
The F9-Kunitzin-OV and Kunitzin-OV were synthesized from C-terminus to N-terminus along
with the sequences by solid-phase peptide synthesis (SPPS). According to the data computed by
ProtParam, the modified F9-Kunitzin-OV possessed less positive charge, but a higher grand average of
hydropathicity than the original peptide does (Table 1).
Biomolecules 2019, 9, 254 5 of 14
Biomolecules 2019, 9, x FOR PEER REVIEW 5 of 13 
 
(a) 
 
(b) 
Figure 3. The identification and characterisation of Kunitzin-OV: (a) the 240 min reverse-phase high-
performance liquid chromatography (HPLC) chromatogram of the skin secretion of Odorrana 
versabilis. The elution position is indicated with an arrow. The components were monitored at a 
wavelength of 214 nm; (b) peptide fragment spectrum collected on an LCQ Fleet ion trap mass 
spectrometer. The peptide was fragmented randomly at each peptide bond, b- and y-ions are 
indicated in blue and red. 
3.3. Synthesis of Kunitzin-OV and Phe-Substituted Variant 
The F9-Kunitzin-OV and Kunitzin-OV were synthesized from C-terminus to N-terminus along 
with the sequences by solid-phase peptide synthesis (SPPS). According to the data computed by 
ProtParam, the modified F9-Kunitzin-OV possessed less positive charge, but a higher grand average 
of hydropathicity than the original peptide does (Table 1). 
  
3. The identification and characterisati n of Kunitzin-OV: (a) the 240 min reverse-phase
high-performance liquid chromatography (HPLC) chromatogram of the skin secretion of
ilis. The elution position is indicated ith . The co ponents ere itored t
l t f ; ( ) ti f t tr ll te l t i t
tr t r. The peptide was fragment d randomly at each peptide bond, b- and y-ions are indicated
i blue and red.
Biomolecules 2019, 9, 254 6 of 14
Table 1. Sequences and physicochemical properties of Kunitzin-OV and its Phe-substituted variant.
Sequence Net Charge GRAVY 1
Kunitzin-OV ALKYPFRCKAAFC +3 0.354
F9-Kunitzin-OV ALKYPFRCFAAFC +2 0.869
1 GRAVY—the grand average of hydropathicity.
3.4. Antimicrobial/Haemolytic Assay of Kunitzin-OV and F9-Substituted Analogue
No significant antimicrobial activities were observed for Kunitzin-OV and its F9-substituted
analogue (Table 2). Both peptides showed little haemolytic activity (less than 10%) even at concentrations
up to 512 µM (Figure 4).
Table 2. Minimum inhibitory concentrations (MICs) determined for the Gram-positive bacterium,
Staphylococcus aureus (S. aureus), the Gram-negative bacterium, Escherichia coli (E. coli), and the yeast,
Candida albicans (C. albicans) with Kunitzin-OV and Kunitzin-OV variant. The blank control was
established by the culture medium, and the positive control represented growth culture.
Peptides Sequence
Minimum Inhibitory Concentration (µM)
S. aureus E. coli C. albicans
Kunitzin-OV ALKYPFRCKAAFC 512 512 512
F9-Kunitzin-OV ALKYPFRCFAAFC 512 512 512
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low degree of permeable effect on the E. coli cell membrane. 
Figure 4. The haemolytic activity of Kunitzin-OV and F9-Kunitzin-OV against horse blood cells. Triton
X-100 was severed as a positive control with 100% haemolysis.
3.5. E. coli Cell Membrane Permeability of Kunitzin-OV
The cell membrane permeabilization activity of Kunitzin-OV was tested with its MIC value
(512 µM), as shown in Figure 5. Compared to the cell-penetrating melittin, Kunitzin-OV only exhibited
a low degree of permeable effect on the E. coli cell membrane.
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Figure 5. The cell membrane permeability of Kunitzin-OV with phosphate-buffered saline (PBS) as a
negative control and melittin as a positive control.
3.6. Trypsin/Chymotrypsin Inhibitory Activity of Kunizin- V and Phe-Substituted Analogue
Kunitzin-OV displayed trypsin inhibitory activity with a Ki value of 3.042 .359 µM. With a Lys-9
residue occupying the P1 position, no chymotrypsin activity was observed. Whereas, when the Lys-9 at P1
position was substituted by a Phe, trypsin inhibitory activity disappeared, and chymotrypsin optimized
inhibitory activity was obtained, with a Ki value of 11.810 ± 2.087 µM. Besides Ki values, progress curves
and Morrison plots of Kunitzin-OV and its variant are also shown (Figure 6). The chicken egg white
trypsin ibitor Typ III-O, which i also called ovomucoid inhibitor, was served as a contrast, and it
showed faster and stronger inhibitory efficacy on trypsin than Kunitzin-OV (Figure 7).
Biomolecules 2019, 9, x FOR PEER REVIEW 7 of 13 
 
Figure 5. The cell membrane permeability of Kunitzin-OV with phosphate-buffered saline (PBS) as a 
negative control and melittin as a positive control. 
3.6. Trypsin/Chymotrypsin Inhibitory Activity of Kunizin-OV and Phe-Substituted Analogue 
Kunitzin-OV displayed a trypsin inhibitory activity wit  a Ki value of 3.042 ± 0.359 µM. With a 
Lys-9 residue occupying the P1 position, no chymotrypsin activity was observed. Whereas, when the 
Lys-9 at P1 position was substitu ed by a Phe, tryps n inhibitory activity disappeared, and 
chymotrypsin optimized inhibitory activity was obtained, with a Ki value of 11.810 ± 2.087 µM. 
Besides Ki values, progress curves and Morrison plots of Kunitzin-OV and its variant are also shown 
(Figure 6). The chicken egg white trypsin inhibitor Type III-O, which is also called ovomucoid 
inhibitor, was served as a contrast, and it showed faster and stronger inhibitory efficacy on trypsin 
than Kunitzin-OV (Figure 7). 
  
(a) 
  
(b) 
Vi
 (R
FU
/m
in)
Figure 6. Cont.
Biomolecules 2019, 9, 254 8 of 14
Biomolecules 2019, 9, x FOR PEER REVIEW 8 of 13 
(c) 
Figure 6. Trypsin/chymotrypsin inhibitory activities: (a) Reactive curves and corresponding Morrison 
plot of trypsin inhibition of Kunitzin-OV in various concentrations; (b) Reactive curves and 
corresponding Morrison plot of chymotrypsin inhibition of F9-Kunitzin-OV in various concentrations; 
(c) Reactive curves and corresponding Morrison plot of trypsin inhibition of ovomucoid inhibitor 
(chicken) in various concentrations. 
3.7. Trypsin Cleavage Assay of Kunitzin-OV 
The synthetic replicate of Kunitzin-OV was subjected to trypsin cleavage assay. It can be seen 
from the MALDI-TOF results that Kunitzin-OV was cleaved into small catabolites along with the 
time (Figure 7). The obtained fragments were marked in the figure, which shows that the catabolites 
were cleaved through typical trypsin cleavage sites. 
 
(a) 
 
(b) 
Figure 6. Trypsin/chymotrypsin inhibitory activities: (a) Reactive curves and corresponding Morrison
plot of trypsin inhibition of Kunitzin-OV in various concentrations; (b) Reactive curves and corresponding
Morrison plot of chymotrypsin inhibition of F9-Kunitzin-OV in various concentrations; (c) Reactive
curves and corresponding Morrison plot of trypsin inhibition of ovomucoid inhibitor (chicken) in
various concentrations.
3.7. Trypsin Cleavage Assay of Kunitzin-OV
The synthetic replicate of Kunitzin-OV was subjected to trypsin cleavage assay. It can be seen
from the MALDI-TOF results that Kunitzin-OV was cleaved into small catabolites along with the time
(Figure 7). The obtained fragments were marked in the figure, which shows that the catabolites were
cleaved through typical trypsin cleavage sites.
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To date, hundreds of functional peptides have been isolated from Odorrana skin secretion, not only
many potent antimicrobial peptides but also trypsin inhibitors. For instance, a small trypsin inhibitor
OGTI was identified from Odorrana grahami (with a Ki value of 0.4 µM) in 2008 [14], and a potent
Bowman–Birk-type trypsin inhibitor (with a Ki value of 388 ± 28 nM) was initially isolated from the
skin of the Hejiang odorous frog, Odorrana hejiangensis [11]. Additionally, a new class of protease
inhibitor with trypsin inhibition (with a Ki of 5.56 mM) was reported in the skin secretion of Odorrana
schmackeri [12].
In this study, a novel peptide was isolated from the skin secretion of the Chinese bamboo leaf
odorous frog, Odorrana versabilis. It is a short peptide composed of 13 amino acid residues, which
contain a single disulfide bond (-CKAAFC-) located at the C-terminal between Cys8 and Cys13.
The primary sequence of this novel peptide was subjected to homology searches using NCBI-BLAST,
and its C-terminal part was 100% identical to the corresponding sequence of a kunitzin precursor.
The name kunitzin was initially reported for two trypsin inhibitors, Kunitzin-RE and Kunitzin-OS,
from Rana esculenta and Odorrana schmackeri, respectively [12]. Based on the comparison of structure
homology, the six-residue disulfide bond of the novel peptide is identical to the C-terminal loop of the
previously reported kunitzins, while their amino acid residues are arranged in a different order at the
N-terminal. Besides, the novel peptide in this study was determined to possess the ability to inhibit
trypsin as kunitzins do.
In the antimicrobial assay, Kunitzin-OV exhibited no significant inhibition against either bacteria
or yeast, which was quite different from the results obtained from the test on Kunitzin-RE (MIC
E. coli = 30µM) [12], as this reported peptide possessed a narrow-spectrum antimicrobial activity against
Gram-negative bacterium E. coli. The results just corresponded to the physicochemical properties
of these two peptides. Kunitzin-RE contains one more net charge (+4) and a higher GRAVY index
(0.567) than Kunitzin-OV, in which a more positive charge brings better electrostatic attraction between
a cationic peptide and an anionic bacteria membrane surface, and higher hydrophobicity promotes
the peptide interaction with the hydrophobic tail of bacteria bilayer [19]. Moreover, these results also
suggested that the disulfide bond (-CKAAFC-) is not a decisive factor for antimicrobial activity, as
Chen [12] and his colleagues also synthesized this single loop alone to test its antimicrobial properties,
and no activity was observed against all tested microbes. In 1995, Sonohara and his partners [20]
investigated the differences between the surface of S. aureus and E. coli via electrophoretic mobility
measurements, and they found that E. coli had a more negatively charged and less soft surface than
that of S. aureus. Meanwhile, C. albicans is a potentially pathogenic yeast. It is a eukaryotic organism
and has different cell wall components than bacteria [21]. These may explain why Kunitzin-RE only
showed limited activity against E. coli.
As we known, melittin is a potent antimicrobial peptide (AMP) with broad-spectrum activities,
besides it is also one of famous membrane-penetrating AMPs that is able to induce pore formation
of the bacteria cell membrane [22]. It is clear that Kunitzin-OV exhibited much lower potency than
melittin to permeabilize the cell membrane of E. coli, which could explain the weak antimicrobial
activity of Kunitzin-OV.
In a further investigation, Kunitzin-OV was subjected to protease inhibitor assay, and it showed
inhibition of trypsin with a Ki value of 3.042 µM and no inhibitory activity towards chymotrypsin.
Based on the bioinformatics analysis, the C-terminal disulphide-bridged loop of Kunitzin-OV displayed
a high degree of similarity to the reactive centre of several Kunitz-type inhibitors from different sources
(Table 3). The P1 position of all these inhibitors is occupied by either a Lys or an Arg residue.
Additionally, a study of the evolutionary trace about 74 Kunitz sequences has appeared that the P4
position of those Kunitz proteins is completely conserved as a glycine residue when partitioning
identity cut-offs at high values [23]. However, Kunitzin-OV contains the conserved P1 residue without
a Gly at the P4 position. Additionally, including the other two kuniztins mentioned above, OGTI [14]
is also a trypsin inhibitor (AVNIPFKVHFRCKAAFC) from Odorrana grahami that shows the identical
reaction loop but the absence of a Gly at P4.
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Table 3. Comparison of the reactive sites of Kunitzin-OV with different kinds of Kunitz-type protease
inhibitors. The reactive sites are highlighted.
Name Sequence Length Reactive Site Source
Kunitzin-OV 13 -F R C K A A F- This study
VKTO1_HAPHA 55 -G R C K A S F- UniProtKB-D2Y2Q6
VKTCT_OPHHA 58 -G F C K A Y I- UniProtKB-B6RLX2
BPT1_BOVIN 58 -G P C K A R I- UniProtKB-P00974
CSTI_BOMMO 55 -G P C K G S F- UniProtKB-P81902
SPIT2_HUMAN domain 2 51 -G P C R A S F- UniProtKB-O43291
AMBP_HUMAN domain 2 51 -G P C R A F I- UniProtKB-P02760
VKT_OXYSC 51 -G P C R A A I- UniProtKB-B7S4N9
Furthermore, the Ishikawain-2 from Odorrana ishikawae, which also contains the C-terminal
six-residue loop, was first considered as an antimicrobial peptide, but no antimicrobial activity was
found after testing [20]. We thought it was highly likely to be a member of this particular kind of
trypsin inhibitor, but surely further research is needed to prove it. Therefore, we considered that
these inhibitors from amphibian skin secretions were a form of short and unique inhibition motif for
possessing the self-defence efficiently.
By replacing Lys-9 with Phe, the site-substituted analogue showed an optimized chymotrypsin
inhibitory activity, while the inhibitory activity towards trypsin was eliminated. Generally, Kunitz-type
inhibitors achieve their inhibition through a standard mechanism (canonical inhibition). They interact
with the target via a tight and non-covalent bond, which is just like the enzyme-substrate complex [13].
Without any changes of conformation, the inhibitors block the active site of the serine protease, and an
antiparallelβ-sheet is formed between the enzyme and its inhibitor [24]. The so-called protease-binding
loop refers to an extended, solvent-exposed and convex fragment that has charge of protease inhibitory
activity, and the location of the reactive site (P1-P’1 peptide bond) is in the most visible part of this
loop [1]. Crossing from P3 to P’3 position, the protease-binding loop is highly complementary to the
concave enzyme active site [1].
As known, the catalysis of serine protease is specified by their S1 pocket, for trypsin, its negative
charged Asp189-based S1 pocket selectively contacts with basic residues. Whilst, the S1 position of
chymotrypsin, which contains phenyl group inside the pocket, shows higher affinity to aromatic
residues [25]. Thus, in this study, -RCKAAF- is the trypsin-bonding loop and the reactive site (K-A) is
complementary to the trypsin active site. Once the Lys-9 (P1 position) was substituted by Phe, the
trypsin inhibitory activity vanished. It also suggested that the variant contains the reactive site (K-F)
which works for the inhibition of chymotrypsin. It is a natural selection that a Lys residue occupied the
P1 position of kunitzins to regulate the inhibitory activity towards trypsin.
In the case of Kunitzin-RE, the result is slightly different. Weak inhibition of trypsin (Ki = 48.37 µM)
was still observed for the substituted analogue [12]. Combined with the data obtained from trypsin
cleavage, each segment of both Kunitzin-OV and Kunitzin-RE was cleaved by trypsin via typical
cleavage site Lys and Arg. The difference was the C-terminal function loop of Kunitzin-OV was
catabolized via Lys-9, while this did not happen to Kunitzin-RE. Therefore, we assumed that the Lys
close to the region of the protease-binding loop could act as a competitive position for trypsin activity
and protect the functional disulphide loop from cleavage. In this way, the inhibitory activity may
be more stable and productive. It has been described that association energy can be influenced by
residues around the protease-binding loop and even from a distant region, and these residues can still
contact the enzyme [4].
Based on the catabolites obtained in the trypsin cleavage assay, Kunitzin-OV was catabolized by
trypsin through the classical cleavage sites Lys and Arg. These data may imply that Kunitzin-OV
achieves its inhibition by competing with the substrate for the active site of the trypsin. Besides, the
reactive site (K-A) was not cleaved at the very end of the incubation, which means this sequence was
catabolized in a highly ordered way and the inhibitory reaction would continue until the reactive site
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was cleaved. Nevertheless, the reaction loop (-RCKAAF-) was cleaved via Lys-9 residue after 2 min
of incubation, which might result in an unstable structure and a less potent activity of Kunitzin-OV.
This may also explain why the ovomucoid inhibitor (chicken) showed more potent inhibitory activity
than Kunitzin-OV did, as the ovomucoid consists of more than 200 amino acid residues that could
stabilize the conformation. It might improve the affinity to the reaction centre of trypsin and slow
down the degradation of the inhibitor. As a consequence, the short sequence of Kunitzin-OV was
degraded by trypsin easily. Interestingly, it has been proved that inhibitors with a short sequence
showed higher thermostability than ovomuciod inhibitors did [26], which implies that to increase
the structural stability and keep the short sequence at the same time is an efficient way for the small
peptide inhibitor to optimize the inhibitory activity.
As mentioned above, the addition of a Lys or Arg residue around the loop may be an efficient
way to protect the P1 position from cleavage and thus improve the peptide stability and efficacy.
Further research needs to be done to prove this. The study of Kunitzin-OV may propose a new insight
for trypsin inhibitor-related therapeutics because they have been regarded as potential therapeutic
molecules in the treatment of chronic diseases, like obesity [6].
5. Conclusions
In summary, Kunitzin-OV is a novel trypsin inhibitor isolated from the defensive skin of the
odorous frog, Odorrana versabilis. It is considered as a member of kunitzins, which is a non-typical
Kunitz-like trypsin inhibitor with a highly conserved reactive site (K-A) and quite a short sequence.
This study of Kunitzin-OV provided a new option for the design of trypsin inhibitors. Moreover, the
frog skin-derived kunitzins, which exhibited a short sequence, potent trypsin inhibitory activities, and
little cytotoxicity, have great potential to be natural drugs.
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